Hot Jobs–Pharmaceutical and Biotech–located in the Mid-Atlantic Region (Maryland and Washington DC areas) Antibody Scientist–Involved in screening antibodies, design peptides, write methods, work with antibody vendors. Should understand analytical methods such as Mass Spec, HPLC. This person will not be a bench chemist doing ELISA’s all day. Will support the R & D department, ...

Last year's global food crisis made millions for agro-giant Monsanto. Tim Hunt of Ethical Consumer magazine fails to find any redeeming features in this corporate behemoth.Try looking objectively at biotech firm Monsanto, a company that only ever seems to receive a negative press, and see if you can find any redeeming features – any ray of light emanating from this seeming black hole of ...

November 27, 2009 Shares of Biotech HOLDRS (AMEX: BBH) declined to under $90.00 a share since reaching their 2009 highs at 105.00 a share on July 30. BBH has slowly recovered but has now reached a critical level in its advance. The 61.8% retracement resistance level, for the entire July to October correction, is at $98.76. On Wednesday, November 25, BBH closed at $98.64, just a fraction below ...

... find out. That is why they make the big bucks. The average biotech CEO is something of an even bigger outlier. Armed with a Ph. ... tasks out there. . . as is finding the market's top biotech stocks. Advertisement Thanks to a little-known California law, this wind ... anymore to keep their pipelines full. That's why tiny biotech research companies can be bought out in an instant these days ...

... its recent run. Recent press releases from several biotech companies have not garnered much response in terms of upward ... investors also thought that it was time to take some profits off the table. Because the biotech sector did enjoy such a run up, it only makes sense ... investor who has a long term and PATIENT outlook. My take on the biotech pullback summed up in a short sentence: I don't ...

... Pitiful productivity. Andrew Hessell, once employed by a major biotech drug developer (unnamed) and now an evangelist of synthetic biology ... the territory. And that, in Hessel’s view, makes biotech the next IT. The price of gene sequencing is falling precipitously; ... , protective measures, tests and measurements. Make biotech more like infotech, Hessel says, and it will happen. Ted Greenwald is ...